Fallopian Tube Cancer
462
46
76
247
Key Insights
Highlights
Success Rate
78% trial completion
Published Results
132 trials with published results (29%)
Research Maturity
247 completed trials (53% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
14.9%
69 terminated out of 462 trials
78.2%
-8.3% vs benchmark
12%
55 trials in Phase 3/4
53%
132 of 247 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 247 completed trials
Clinical Trials (462)
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
A Study of XMT-1660 in Participants With Solid Tumors
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian Tube or Primary Peritoneal Cancer (HGSEC): The t-BRCA Study
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers
Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas
Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
Using Aspirin to Improve Immunological Features of Ovarian Tumors